Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

l StudiesThe two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult subjects.  Subjects with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. These studies were designed to evaluate safety and compare the response to treatment in subjects during and after a 10-day course of therapy. The primary endpoint was non-inferiority compared to Vancocin in clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator).  If cured, subjects were monitored for a subsequent four-week period to evaluate recurrence, which was a secondary endpoint.  Global cure, also a secondary endpoint, was defined as patients who were cured and did not have a recurrence during this subsequent four-week period. In both of these studies, fidaxomicin achieved its primary endpoint of non-inferiority compared to Vancocin.  Fidaxomicin was also statistically superior to Vancocin in global cure rate and in reducing recurrences of CDI.

About Clostridium difficile InfectionCDI has become a significant medical problem in hospitals, long-term care facilities, and in the community.  It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produces toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, and thus allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially res
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... of The Kings Daughters (CHKD) is leading the clinical ... to develop a device to measure the precise temperature ... Health (NIH) grant stems from recent studies showing that ... the incidence of Cerebral Palsy, other neurological damage, and ...
... PALO ALTO, Calif., Aug. 31 Anacor Pharmaceuticals,announced today ... S-1 with,the Securities and Exchange Commission for a proposed ... of the shares in the proposed,offering are being sold ... be Morgan Stanley & Co.,Incorporated as sole book runner, ...
... company offers innovative casting, splinting and bracing ... Enova Medical Technologies,Inc. of St. Paul, ... Aspen,Colo., are pleased to announce the launch ... will develop and commercialize innovative orthopedic,support devices. ...
Cached Biology Technology:NIH grants $750,000 to develop device to determine temperature of neonate's brain 2Anacor Files Registration Statement for Initial Public Offering 2Enova Medical Launches Exos Corporation 2
(Date:7/9/2014)... us, many backyard cooks are turning to more healthful ... low fat can sometimes mean low satisfaction. Now researchers ... in low-fat wieners that are made with olive oil ... ACS, Journal of Agricultural and Food Chemistry . ... consumers have come to expect just the right amount ...
(Date:7/9/2014)... Adlie penguins shows that the population is 3.79 ... previously estimated. Adlie penguins have long been considered ... the effects of climate change and fishing in ... imagery, researchers from Stony Brook University and University ... permits regular monitoring of Adlie penguins across their ...
(Date:7/9/2014)... of an economy driven by methane, the primary component of ... a production boom. It has poised the country as a ... doubts over just how climate-friendly it is, according to an ... weekly news magazine of the American Chemical Society. , In ... that when burned as a fuel to produce electricity, methane ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... (NYSE:JWa, JWb), a global provider of content and ... and scholarly research; professional development; and education, today ... Library. PDFs read using the ReadCube Web Reader ... and direct access to supplemental content, making it ...
... Colo., USA GSA Bulletin papers published online ... Canada, Mexico, Spain, the UK, and New Zealand. Multiple locations ... Canada, New Zealand, and Guatemala. Papers cover , ... region, USA;, 2. Tectonics, salt, and the fossil forests of ...
... ever wondered why, and how, shoals of fish are comprised of ... Ward, from the University of Sydney in Australia, and Suzanne Currie, ... of different sensory cues to locate shoal-mates, but they are able ... size as themselves. Using these cues, they can form a group ...
Cached Biology News:GSA Bulletin starts 2013 with 13 new papers published online ahead of print 2GSA Bulletin starts 2013 with 13 new papers published online ahead of print 3GSA Bulletin starts 2013 with 13 new papers published online ahead of print 4GSA Bulletin starts 2013 with 13 new papers published online ahead of print 5GSA Bulletin starts 2013 with 13 new papers published online ahead of print 6GSA Bulletin starts 2013 with 13 new papers published online ahead of print 7GSA Bulletin starts 2013 with 13 new papers published online ahead of print 8GSA Bulletin starts 2013 with 13 new papers published online ahead of print 9GSA Bulletin starts 2013 with 13 new papers published online ahead of print 10GSA Bulletin starts 2013 with 13 new papers published online ahead of print 11Nothing fishy about swimming with same-sized mates 2
... gasket slides/kit Gasket slide kit (1x 22K ... or Gasket slide kit ... disposable gasket slides offered in either 11K or 22K ... The gaskets are carefully fabricated and batch tested ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
... Oligo Microarray Kit (V2), 2 x ... characterize expression of many thousands of ... during important biological processes. Each microarray ... known ORFs from the S288C strain ...
Biology Products: